Class / Patent application number | Description | Number of patent applications / Date published |
514226200 | Chalcogen or nitrogen attached indirectly to the phenothiazine ring nitrogen by acyclic nonionic bonding | 25 |
20080207604 | Materials and methods relating to protein aggregation in neurodegenerative disease - The present invention relates to methods for the detection of substances capable of modulating or inhibiting pathological tau-tau protein association. The methods of the present invention are particularly useful in screening substances for the prophylaxis and treatment of Alzheiemer's disease. | 08-28-2008 |
20080261960 | Biologically active methylene blue derivatives - The present invention relates to a phenothiazinium compound of Formula (I): | 10-23-2008 |
20080269205 | METHODS TO PREVENT VERTICAL TRANSMISSION OF INFECTIOUS DISEASES - The present invention presents a method of preventing vertical transmission of an infectious disease comprising: (a) applying a photosensitizing composition to host tissues of birth canal of a mother during the intrapartum period; and (b) applying light to the host tissues after the step (a) at a wavelength absorbed by the photosensitizing composition so as to inhibit or eliminate infectious disease microorganisms that come into contact with the host tissues. The infectious disease may be caused by human immunodeficiency virus type 1, hepatitis B virus, hepatitis C virus, Group B | 10-30-2008 |
20080269206 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF - The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-6 or encompassed by formulas I-VI) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease. | 10-30-2008 |
20090054419 | 3,7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE - This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R | 02-26-2009 |
20090163481 | PPAR-DELTA LIGANDS AND METHODS OF THEIR USE - The disclosure provides compounds, compositions, and methods for modulating PPARĪ“ receptor. In one embodiment, the compounds of the disclosure comprise a tri-substituted thiazole group. The substituent at the 2-position of the thiazole group provides steric bulk to the compounds. The compounds, compositions, and methods may be useful, for example, in the treatment of cancer. | 06-25-2009 |
20090291943 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS - Process for preparing compounds of the diaminophenothiazinium type comprising a step for purification of derivatives (II). The products resulting from this process have a high degree of purity. Use of these compounds for the preparation of medicaments. | 11-26-2009 |
20100029624 | Male Contraceptive - A compound having formula I. R | 02-04-2010 |
20100093710 | GALENICAL FORM FOR THE ADMINISTRATION OF PARACETAMOL BY TRANSMUCOUS MEANS - A galenical form for the transmucous administration of at least one active ingredient, characterized in that the active ingredient is paracetamol in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 10% by mass of alcohol so as to allow fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for production and the uses of the galenical form are also disclosed. | 04-15-2010 |
20100113431 | N-METHYL PIPERAZINE MODULATORS OF H1 RECEPTOR - The present invention relates to new N-methyl piperazine modulators of H1 receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 05-06-2010 |
20100113432 | PHENOTHIAZINE MODULATORS OF D2 RECEPTORS AND 5-HT2 RECEPTORS - The present invention relates to new phenothiazine modulators of D2 receptor activity and/or 5-HT2 receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 05-06-2010 |
20100120756 | PHENOTHIAZINE MODULATORS OF H1 RECEPTORS - The present invention relates to new phenothiazine modulators of H1 receptors, pharmaceutical compositions thereof, and methods of use thereof. | 05-13-2010 |
20110028459 | Wound Healing - A phenothiazinium compound, compositions and medicaments for use in promoting wound healing and a method for promoting wound healing or cosmetic use by applying or administering a phenothiazinium compound to a wound site or the skin, and optionally exposing the wound site or skin to light. | 02-03-2011 |
20110034447 | TDP-43-STORING CELL MODEL - Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having, introduced therein, a promoter capable of functioning in a host cell and a mutant TDP-43 gene. | 02-10-2011 |
20110092493 | Dose-controlled transdermal promethazine compositions and methods of use - The current invention provides formulations for transdermal delivery of promethazine which achieve delivery of the drug with consistent plasma levels. The topical formulations of the invention are superior to both rectal suppositories and oral dosage forms in that variable blood levels, first-pass metabolism, unpredictable peaks in blood levels, and variable bioavailability are minimized. Formulations of the invention provide antiemetic and antipruritic relief to patients in need of treatment while minimizing side effects and adverse reactions known to occur with other routes of administration and other formulations. | 04-21-2011 |
20110118242 | 3,7-DIAMINO-10H-PHINOTHIAZINE SALTS AND THEIR USE - This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of the following formula: | 05-19-2011 |
20110294795 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS - Described are compositions and methods of making high purity diaminophenothiazinium compounds of the following formula | 12-01-2011 |
20120046279 | Oligomer-Phenothiazine Conjugates - The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds. | 02-23-2012 |
20120101089 | Anti-Emetic Substance - The present invention provides a therapeutic solution for effective control of symptoms related to nausea and vomiting. The therapeutic solution is a pharmaceutical composition which combines anti-emetics of different classes. These classes include dopamine receptor antagonists, serotonin receptor antagonists, butyrphenones, and neurokinin receptor antagonists. The combination of different anti-emetics mitigates adverse affects of a single anti-emetic alone while increasing drug efficacy and decreasing cost of administration to the individual patient. | 04-26-2012 |
20130252947 | BMP-2 Upregulating Compounds For Healing Bone Tissue And Screening Methods For Selecting Such Compounds - The present disclosure relates to a method to stimulate endogenous BMP-2 up-regulation in a subject which method comprises administering to a subject an effective amount of an H1 receptor antagonist, whereby endogenous BMP-2 up-regulation is stimulated in said subject. Also provided is a pharmaceutical formulation including an H1 receptor antagonist present in an effective amount to stimulate BMP-2 up-regulation in a subject and a kit. | 09-26-2013 |
20140005179 | ORAL PHARMACEUTICAL DISPERSION COMPOSITIONS | 01-02-2014 |
20140066439 | OSTEOCLAST ACTIVITY - Described are medicaments and methods of treating or preventing metabolic bone diseases, such as Critical Illness Related Metabolic Bone Disease or of critical illness induced Osteopenia secondary to ICU Admission by sufficient autophagy inducing compound to inhibit or suppress critical illness enhanced osteoclastogenesis or increased osteoclast differentiation. The methods include administering of an autophagy activating compound to a mammal to: treat or prevent a bone degenerative disorder; slow bone deterioration; restore lost bone; maintain bone mass and/or bone quality or inhibit bone resorption in particularly by inhibiting or reducing a process by which osteoclasts break down bone and release the minerals resulting in a transfer of calcium from bone fluid to the blood. Also described are methods for administering the autophagy activating compound to treat a bone disorder of hyperresorption of bone and/or enhanced activation of osteoclasts. | 03-06-2014 |
20150290211 | PHARMACEUTICAL COMPOSITIONS - Provided herein are methods and compositions for effective pain treatment, which also reduce or eliminate adverse effects. | 10-15-2015 |
20160051559 | 3, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE - Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: | 02-25-2016 |
20160083358 | COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA - The invention provides compositions and methods useful for the treatment of Friedreich's ataxia. In some embodiments, the invention provides compositions and methods useful for inhibiting the ubiquitination of frataxin. | 03-24-2016 |